Fatpos Global has released a report titled “Lyme Disease Diagnostics Devices Market – Analysis of Market Size, Share & Trends for 2021 – 2022 and Forecasts to 2032” which is anticipated to reach USD 3.8 billion by 2032. According to a study by Fatpos Global, the market is anticipated to portray a CAGR of 6.9% between 2022 and 2032. As per the report, the rising prevalence of Lyme disease and a spike in financing from governmental agencies and major corporations for the creation of Lyme disease diagnostic kits are both factors contributing to the growth of the global Lyme Disease Diagnostics Devices Market. Moreover, the rising healthcare spending, expanding government initiatives, and increasing prevalence of new vector-borne diseases are anticipated to drive the growth of the Lyme Disease Diagnostics Devices Market throughout the forecast period.
The market research on Lyme Disease Diagnostics Devices Market includes in-depth insights as:
- Global Lyme Disease Diagnostics Devices Market in North America held the largest market share in the year 2021.
- Global Lyme Disease Diagnostics Devices Market is classified on the basis of Product Type into Serological Test, Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, and Nucleic Acid Test.
- Based on End User, the global Lyme Disease Diagnostics Devices Market is fragmented into Hospitals, Public/Private Laboratories, and Physician’s Office.
- Key players are expected to focus on growth strategies like research and development, mergers and acquisitions, joint ventures, and product launches to sustain themselves in the global market.
“With over 30,000 cases reported to the Centers for Disease Control and Prevention (CDC) annually, Lyme disease is the most common arthropod-borne illness in the United States. Around 85,000 cases are reported each year in Europe, according to the WHO. In England and Wales, more than 3,000 new cases are reported every year. The most cases were reported in central Europe, mainly in Germany, Austria, Slovenia, and the coastal districts of Sweden. According to the Centers for Disease Control and Prevention (CDC), from 324 in 2008 to 415 in 2018, there were more counties with an incidence of less than 10 confirmed cases per 100,000 people. Hence, the rising prevalence of Lyme diseases is significantly driving the Lyme Disease Diagnostics Devices Market.”, said a lead analyst at Fatpos Global.
Lyme Disease is the most widely reported vector-borne disease prevalent in the United States. For the diagnosis of Lyme disease, in-vitro diagnostic (IVD) tools are available. The bacterium Borrelia burgdorferi and, less frequently, Borrelia mayonii are responsible for this illness. Infected blacklegged ticks bite humans to spread the disease. Headache, exhaustion, fever, and an erythema migrans-like skin rash are typical symptoms. Infection can spread to joints, the heart, and the neurological system if it is not treated. Over the ensuing ten years, it is anticipated that there will be an increase in the number of Lyme disease cases. The demand for accurate and effective IVD devices is rising along with the general public’s understanding of Lyme disease.
Lyme Disease Diagnostics Devices Market is categorized on the basis of End User into Hospitals, Public/Private Laboratories, and Physician’s Office. The Public/Private Laboratories segment is projected to lead the market. The need for novel diagnostic procedures that can spot the earliest signs of infection is demonstrated by the fact that serological testing for Lyme Disease might take several weeks to become conclusive after infection. Hospitals use the most up-to-date diagnostic and therapeutic methods and are well-equipped to manage patient flow. Hospitals hold a larger market share in the end-user segment of the market, primarily due to these considerations. Since these labs have all the necessary equipment for Lyme disease testing, the public/private laboratories market will grow at a sizable CAGR throughout the projected period.
Key Players in the Market
Some of the key players operating in the global Lyme Disease Diagnostics Devices Market are Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics, PerkinElmer Inc., Bio-Rad Laboratories, DiaSorin S.p.A, Quidel Corporation, Meridian Bioscience Inc, Graphene Frontiers, T2 Biosystems Inc., IGeneX Inc., Cenogenics Corporation, Ceres Nanosciences Inc., Trinity Biotech plc, Lyme Diagnostics Ltd., and Other Prominent Players.
Get Valuable Insights into Global Lyme Disease Diagnostics Devices Market
In the latest market study conducted by, Fatpos Global thrives to present an unbiased analysis of the global Lyme Disease Diagnostics Devices Market that covers the historical demand data as well as the forecast figures for the period, i.e., 2022-2032. The study includes compelling insights into growth that is witnessed in the market. Global Lyme Disease Diagnostics Devices Market is classified on the basis of Product Type into Serological Test, Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, and Nucleic Acid Test. By Sample, the global Lyme Disease Diagnostics Devices Market is divided into Blood, Cerebrospinal Fluid (CSF), Joint Fluid, and Urine. By End User, the global Lyme Disease Diagnostics Devices Market is divided into Hospitals, Public/Private Laboratories, and Physician’s Office. Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa.